BostonGene Corporation

BostonGene Corporation is a privately held biotechnology company headquartered in Waltham, Massachusetts, dedicated to revolutionizing cancer treatment through personalized medicine. The company's core mission is to power healthcare's transition to personalized medicine by leveraging its AI-based molecular and immune profiling solutions to improve the standard of care, accelerate research, and reduce the overall cost of cancer treatment.

BostonGene offers a suite of AI-powered products and services, including the BostonGene Tumor Portrait™ test, BostonGene Liquid Biopsy test, Immunohistochemistry (IHC) test, and Unknown Primary test, alongside comprehensive immune system profiling. These solutions integrate advanced bioinformatics, multiomic analytics, next-generation sequencing, flow cytometry, and imaging technologies to provide deep insights into tumor biology and the immune microenvironment. The company serves various market segments, including biopharma, healthcare providers, and patients, focusing on precision oncology and life sciences.

Under the leadership of President and CEO Andrew Feinberg, BostonGene has recently engaged in significant strategic collaborations, including partnerships with AstraZeneca (January 2026) to advance oncology drug development and ImmunoGenesis (April 2026) to overcome immunotherapy resistance. The company was also recognized as the "Innovator of the Year" at the 2025 Boston Life Sciences Times Vanguard Awards (March 2026) for its integrated cancer and immune system foundation models. BostonGene continues to expand its impact by unveiling new platforms, such as its disease modeling platform at JSMO 2026, further solidifying its position in AI-driven precision oncology.